加载中
HKSEHealthcareBiotechnology
最新数据
HK$0.30
+HK$0.01 · +3.45%
China NT Pharma Group Company Limited, operating alongside its various subsidiaries, is dedicated to the full spectrum of pharmaceutical activities. This encompasses the research, development, manufacturing, commercialization, and distribution of medicinal products, serving both the People's Republic of China and international territories. The firm develops and markets prescription medications addressing a diverse array of medical conditions, including oncological and hematological diseases, gastrointestinal disorders, central nervous system afflictions, and respiratory illnesses, among other therapeutic fields. In addition to these specialized drugs, it also produces and distributes its proprietary "NT" branded products and generic formulations. Furthermore, the group extends its offerings to include marketing and promotional assistance for suppliers, alongside providing logistics and consulting solutions. Established in 1995, the company maintains its corporate headquarters in Suzhou, People's Republic of China.
最新数据
HK$0.30
+HK$0.01 · +3.45%
盘中时间采用HKT。市场数据可能有所延迟。
China NT Pharma Group Company Limited, operating alongside its various subsidiaries, is dedicated to the full spectrum of pharmaceutical activities. This encompasses the research, development, manufacturing, commercialization, and distribution of medicinal products, serving both the People's Republic of China and international territories. The firm develops and markets prescription medications addressing a diverse array of medical conditions, including oncological and hematological diseases, gastrointestinal disorders, central nervous system afflictions, and respiratory illnesses, among other therapeutic fields. In addition to these specialized drugs, it also produces and distributes its proprietary "NT" branded products and generic formulations. Furthermore, the group extends its offerings to include marketing and promotional assistance for suppliers, alongside providing logistics and consulting solutions. Established in 1995, the company maintains its corporate headquarters in Suzhou, People's Republic of China.
日内区间
当前HK$0.30
52周区间
当前HK$0.30
盘中时间采用HKT。市场数据可能有所延迟。
China NT Pharma Group Company Limited, operating alongside its various subsidiaries, is dedicated to the full spectrum of pharmaceutical activities. This encompasses the research, development, manufacturing, commercialization, and distribution of medicinal products, serving both the People's Republic of China and international territories. The firm develops and markets prescription medications addressing a diverse array of medical conditions, including oncological and hematological diseases, gastrointestinal disorders, central nervous system afflictions, and respiratory illnesses, among other therapeutic fields. In addition to these specialized drugs, it also produces and distributes its proprietary "NT" branded products and generic formulations. Furthermore, the group extends its offerings to include marketing and promotional assistance for suppliers, alongside providing logistics and consulting solutions. Established in 1995, the company maintains its corporate headquarters in Suzhou, People's Republic of China.
日内区间
当前HK$0.30
52周区间
当前HK$0.30
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（CNY） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2415.8万 CNY | 3796万 CNY | 736.6万 CNY | 2.07亿 CNY | 2.27亿 CNY |
| 销货成本 | 1454.8万 CNY | 3270万 CNY | — | 8180.6万 CNY | 8124万 CNY |
| 毛利 | 961万 CNY | 526万 CNY | 736.6万 CNY | 1.25亿 CNY | 1.45亿 CNY |
| 研究与开发 | — | — | — | 376.2万 CNY | 595.9万 CNY |
| 销售、一般及管理费用 | 2197.4万 CNY | 1848.6万 CNY | 5876.2万 CNY | 2262.2万 CNY | 2.31亿 CNY |
| 营业费用 | 2197.4万 CNY | 1848.6万 CNY | 6357.4万 CNY | 2641.7万 CNY | 2.44亿 CNY |
| 利息收入 | 6818 CNY | 1.1万 CNY | 9000 CNY | 4万 CNY | 23.9万 CNY |
| 利息支出 | 2711.95万 CNY | 3154.4万 CNY | 2881.8万 CNY | 3936.5万 CNY | 8872.7万 CNY |
| 折旧和摊销 | 64.4万 CNY | 66万 CNY | 588.1万 CNY | 2107万 CNY | 4224.9万 CNY |
| 营业利润 | −1236.4万 CNY | −1322.6万 CNY | −5620.8万 CNY | −2654.2万 CNY | −9943.3万 CNY |
| 净利润 | −2604.1万 CNY | −5335.7万 CNY | −1.44亿 CNY | −6640.5万 CNY | −1.5亿 CNY |
公司数据更新于 2026年10月16日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
